Schering-Plough MRK

  1. All
  2. Commentary
  3. Headlines
    1. We're Skeptical of a Potential Zoetis Sale Despite Pershing Square's Reported 10% Stake


      Tue, 11 Nov 2014

      human-pharmaceutical companies. During the Pfizer/Wyeth and Merck / Schering mergers, regulators forced significant divestitures ..... untouched. Similarly, a proposed joint venture between Merck and Sanofi’s animal-health units fell apart in

    2. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush


      Fri, 30 May 2014

      background or infrastructure. Merck came to own the consumer products ..... after its 2009 acquisition of Schering - Plough . Back then, Merck faced patent expirations on major ..... asthma drug Singulair — and Schering - Plough had a relatively stronger branded

    3. High-Priced Sale of Consumer Business Strengthens This Big Pharma Firm's Moat


      Wed, 7 May 2014

      bottom line, Merck has been cutting ..... merger with Schering - Plough , which Merck ..... Standard, as Merck has shown reasonable ..... purchase of Schering - Plough at a fair price ..... Further, Merck 's acquisition of Schering - Plough should yield

    4. Stockland Bolsters Balance Sheet Before Escalating Investment in Retail


      Wed, 22 May 2013

      Stockland SGP raised AUD 400 million of additional equity via an institutional placement at AUD 3.88 per security, representing a 2.5

    5. Stockland's Revised Strategy Sees Rebirth of Industrial


      Wed, 15 May 2013

      At the third-quarter update Stockland SGP guided fiscal 2013 earnings per share (EPS) to be down 25% on fiscal 2012. The downgrade to prior guidance for EPS to fall

    6. Stockland's Residential Impairment Overshadows Resilient Commercial Property Result in First Half


      Wed, 13 Feb 2013

      Stockland's SGP first-half fiscal 2013 normalised operating profit fell by 28% to AUD 255 million, largely due to a change to accounting treatment of interest capitalised into residential development. Stockland also impaired inventory held on balance sheet, resulting in a AUD 318 million writedown ...

    7. Lower Developer Margins Expected for Stockland Following Review of Capitalised Interest


      Tue, 22 Jan 2013

      Stockland SGP is undertaking a review of its capitalised interest policy following an escalation in the level of capitalised interest on the

    8. What Next For The Euro-Zone?


      Fri, 6 Jul 2012

      approved the Stability and Growth Pact ( SGP ) in 1997. This called for fiscal monitoring ..... behind Maastricht and especially behind the SGP was “don’t saddle the prudent members ..... Meanwhile, it quickly became apparent that the SGP was unenforceable – largely because the

    9. Merck Reports Strong 3Q Driven by Growth Across Product Portfolio and Lower R&D Costs


      Fri, 28 Oct 2011

      costs helped fuel growth. Merck raised the lower end of ..... across the majority of Merck 's products supported ..... Beyond 2012, we expect Merck to return to growth as ..... cost synergies from the Schering - Plough acquisition. We expect

    10. Merck Reports In-Line 2Q, Launches New Round of Cost Cuts


      Fri, 29 Jul 2011

      drug Victrelis. Given Merck 's strong entrenchment ..... Simponi, and Dulera. Merck is making progress on ..... cost savings from the Schering - Plough acquisition. While we ..... the long term, given Merck 's aggressive cost-cutting

    « Prev12345Next »
    Content Partners